Drug Trial Radar · NCT07944092
Ph 1/2 Study to Evaluate Safety & Tolerability of FMC-242 Alone and in Combination in Adults With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
282
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- Frontier Medicines CorporationIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if treatment in adults with select solid tumors with FMC-242 alone and in combinations with other cancer drugs is safe and effective. The main questions it aims to answer are: Is treatment with FMC-242 alone safe and tolerable and at what dose? Is treatment with FMC-242 combined other cancer drugs safe and tolerable and at what doses? Participants will need to come to the clinic to have the following: * Physical exams to see if there are any side effects * Standard lab tests to observe blood counts and other values * ECGs to measure heart signals * Blood drawn to measure how the drugs are being metabolized * Imaging such as CT scans to monitor if the cancer is growing or not
Conditions
- Locally Advanced Solid Tumor
Interventions
FMC-242Drug
PI3Kα:RAS breaker
Trastuzumab (or biosimilar)Drug
HER2 targeting agent
Fulvestrant (or generic)Drug
selective estrogen receptor degrader
Pan (K)RAS inhibitorDrug
Pan (K)RAS inhibitor
FMC-376Drug
KRAS G12C inhibitor (experimental)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1 and Phase 2: Adverse EventsTime frame: Approximately 24 months
- Phase 1 : Dose Limiting ToxicitiesTime frame: Up to 21 or 28 days
- Phase 2: Overall Response RateTime frame: Approximately 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.